Home Cart Sign in  
Chemical Structure| 12650-69-0 Chemical Structure| 12650-69-0

Structure of Mupirocin
CAS No.: 12650-69-0

Chemical Structure| 12650-69-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Mupirocin is an antibiotic of the monoxycarbolic acid class and an isoleucyl t-RNA synthetase inhibitor that effective against Gram-positive bacteria, including MRSA.

Synonyms: BRL-4910A; Pseudomonic acid

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mupirocin

CAS No. :12650-69-0
Formula : C26H44O9
M.W : 500.62
SMILES Code : O=C(O)CCCCCCCCOC(/C=C(C)/C[C@H]1[C@H](O)[C@H](O)[C@@H](C[C@@H]2O[C@H]2[C@H]([C@@H](O)C)C)CO1)=O
Synonyms :
BRL-4910A; Pseudomonic acid
MDL No. :MFCD01711620
InChI Key :MINDHVHHQZYEEK-HBBNESRFSA-N
Pubchem ID :446596

Safety of Mupirocin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H317
Precautionary Statements:P261-P280

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Cephalosporin-resistant Neisseria gonorrhoeae 0.03 µg/mL Evaluate the antibacterial activity of Nano-mupirocin against cephalosporin-resistant Neisseria gonorrhoeae, showing full activity PMC8706398
Vancomycin-resistant Enterococcus faecium (VRE) 1 µg/mL Evaluate the antibacterial activity of Nano-mupirocin against VRE, showing full activity against vancomycin-resistant Enterococcus faecium PMC8706398
Methicillin-resistant Staphylococcus aureus (MRSA) 0.5 µg/mL Evaluate the antibacterial activity of Nano-mupirocin against MRSA, showing full activity against methicillin-resistant Staphylococcus aureus PMC8706398
HepG2 cells 0 to 100 μM 48 hours Evaluate the inhibitory effect of Mupirocin on HepG2 cell viability, results showed cells were not sensitive to Mupirocin PMC7062795
MCF7 cells 0 to 100 μM 48 hours Evaluate the inhibitory effect of Mupirocin on MCF7 cell viability, results showed a dose- and time-dependent decrease in cell viability PMC7062795
HCT116 cells 0 to 100 μM 48 hours Evaluate the inhibitory effect of Mupirocin on HCT116 cell viability, results showed cell viability decreased from 100% to 65.95% PMC7062795
Enterococcus faecium 0.25–1 µg/mL Evaluate the antibacterial activity of Nano-mupirocin against Enterococcus faecium, showing low MIC values PMC8706398
Streptococcus pyogenes ≤0.25 µg/mL Evaluate the antibacterial activity of Nano-mupirocin against Streptococcus pyogenes, showing similar MIC values to free Mupirocin PMC8706398
Streptococcus pneumoniae 2 µg/mL Evaluate the antibacterial activity of Nano-mupirocin against Streptococcus pneumoniae, showing higher MIC values than free Mupirocin PMC8706398
Staphylococcus aureus 0.5 µg/mL Evaluate the antibacterial activity of Nano-mupirocin against Staphylococcus aureus, showing MIC values 2-4 times higher than free Mupirocin PMC8706398
Normal human epidermal keratinocytes (NHEKs) 0 μM, 10 μM, 50 μM, 75 μM, 100 μM 24 hours, 48 hours Mupirocin inhibited proliferation of PLEKs and promoted their apoptosis, possibly related to the STAT3 signaling pathway PMC9682813

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mouse MRSA wound infection model Topical administration 2% w/v Once daily for 3 days To evaluate the therapeutic effect of mupirocin on MRSA-infected wounds, results showed that mupirocin significantly reduced bacterial counts, comparable to 2% mupirocin ointment. PMC5711939
BALB/C mice MRSA skin infection model Topical administration 2% Once daily for 4 days Evaluate the therapeutic effect of mupirocin on MRSA skin infection, results showed mupirocin significantly reduced bacterial load PMC4622452
Sprague Dawley Crl:CD (SD) rats Pharmacokinetic model Intravenous and intramuscular 10, 30, 100 mg/kg (IV) and 2.6 mg/animal (IV Nano-mupirocin) Administered on Days 1, 4, 7, 9, 11 and 14 Evaluate the pharmacokinetic properties of Nano-mupirocin in rats, showing plasma concentrations proportional to dose and no significant accumulation PMC8706398
C57BL/6J mice IMQ-induced psoriasis-like skin inflammation model Topical application 0.6 g (2%) 6 consecutive days Mupirocin reversed IMQ-induced keratinocyte proliferation, expression of inflammatory cytokines, and infiltration of immune cells PMC9682813
BALB/cAnNHsd female mice Lethal malaria infection model Intraperitoneal injection 2.5 mg/kg/day Once daily for 4 days Evaluate the therapeutic effect of mupirocin on lethal malaria infection, results showed mupirocin was unable to control primary malaria infection PMC3682711
BALB/c mice MRSA skin infection model Topical administration 2% Twice daily for 5 days To evaluate the efficacy of mupirocin in a MRSA skin infection model. Results showed that 2% mupirocin reduced bacterial load by 2.63 ± 0.14 log10, but was less effective than 2% auranofin (3.64 ± 0.14 log10). PMC4792765
Mice S. aureus skin wound infection model Topical application 2% mupirocin ointment Starting at 4 hours post-inoculation, every 12 hours for 7 days To evaluate the efficacy of mupirocin against USA300 MRSA skin infection, results showed minimal clinical activity against this USA300 strain, resulting in only a 2-fold reduction in bacterial burden PMC3059384

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01152593 Surgical Wound Infection|Cesar... More >>ean Section|Staphylococcus Aureus Less << UNKNOWN 2025-12-14 Hillel Yaffe Medical Center, H... More >>adera, 38100, Israel Less <<
NCT01949935 Surgical Site Infections PHASE3 COMPLETED 2025-05-13 New Brunswick Heart Centre, Sa... More >>int John Regional Hospital, Saint John, New Brunswick, E2L 4L2, Canada Less <<
NCT02284555 Staphylococcal Infection PHASE4 COMPLETED 2025-11-14 Simbec Reseach Ltd, Wales, CF4... More >>8 4DR, United Kingdom Less <<
NCT00156377 Cross Infection|Staphylococcal... More >> Infections Less << PHASE4 COMPLETED - Institute of Medical Microbiol... More >>ogy, University Hospital of Muenster, Muenster, 48149, Germany Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.00mL

0.40mL

0.20mL

9.99mL

2.00mL

1.00mL

19.98mL

4.00mL

2.00mL

References

 

Historical Records

Categories